2025.10.07

Westlake Genetech Invited to Present at 2025 ESGCT Annual Meeting

Westlake Genetech has been invited to attend and deliver an on-site presentation at the 32nd Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT), to be held at Fibes in Seville, Spain, from October 7 to 10, 2025 (local time).

2025.09.10

Westlake Genetech Wins Championship at 2025 Novo Nordisk x ATLATL EntreStar

On September 10, 2025, the 2025 EntreStar Innovation Competition, co-hosted by Novo Nordisk China R&D Center and ATLATL Innovation Center, concluded successfully in Shanghai. Launched in March 2025, the competition narrowed down to five outstanding innovative teams for the finals following a rigorous preliminary round. Westlake Genetech stood out as the champion with its exceptional project performance.

2025.01.10

Westlake Genetech Presents at 2025 Biotech Showcase™

Westlake Genetech will share its achievements in AI-powered gene therapy at the 2025 Biotech Showcase™.

2025.01.09

Westlake Genetech's R&D Team Improves Split-PE for Efficient In Vivo Genome Editing

On December 31, 2024, members of the Westlake Genetech R&D team published a paper entitled “Improved split prime editors enable efficient in vivo genome editing” online in Cell Reports.

2024.05.06

Westlake Genetech to Showcase Two Research Achievements at 2024 ASGCT Annual Meeting

Westlake Genetech. Ltd. announced participation in the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held at the Baltimore Convention Center in Baltimore, Maryland, from May 7 to 11, 2024 (Eastern Time, USA). The company will deliver two oral presentations, highlighting its leading AAV gene therapy delivery platform and its AAV targeting CNS and muscle, and in vivo CAR-T therapy.

2024.04.05

Lijia Ma's team at Westlake University discovered that the transpeptidase sortase binds nucleic acid molecules and mediates cell labeling with nucleic acids

On April 5, 2024, Lijia Ma(the Founder of Westlake Genetech and researcher at the School of Life Sciences, Westlake University), along with team members, published a research paper titled "The transpeptidase sortase A binds nucleic acids and mediates mammalian cell labeling" in Advanced Science.

2024.02.21

The R&D team of Westlake Genetech was invited to publish a preview

On February 21, 2024, members of the Westlake Genetech R&D team were invited to publish a preview titled "A top variant identification pipeline for protein engineering" in Cell Systems.

2024.02.14

The team from Westlake Genetech developed a machine learning-based prediction model to guide the selection of Cas9 variants

On February 14, 2024, members of the founding team of Westlake Genetech published a paper entitled "Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing" in Cell Reports.

2024.01.26

A practical activity team from Tsinghua University visited our company for research

The team of practical activities from the Department of Automation at Tsinghua University visited Westlake Genetech for research recently.

2024.01.09

WESTLAKE GENETECH TO PRESENT AT BIOTECH SHOWCASE™ 2024

Hangzhou/January 8th–Westlake Genetech, today announced that it is presenting at Biotech Showcase™ 2024. Lijia Ma, Founder, and Chairman of the Board will be presenting Westlake Genetech at Biotech Showcase.

2023.05.16

Lijia Ma's team at Westlake University develops a deep-learning model that accurately predicts the activity and specificity of SpCas9/gRNA.

On May 16, 2023, Lijia Ma(the Founder of Westlake Genetech and researcher at the School of Life Sciences, Westlake University), along with team members, published a research paper in Cell Discovery titled "Deep Sampling of gRNA in the Human Genome and Deep-Learning-Informed Prediction of gRNA Activities".

2022.12.12

PEAC-seq | A new approach for evaluating the safety of gene editing

On December 12, 2022, members of the founding team of Westlake Genetech published a paper entitled "PEAC-seq adopts Prime Editor to detect CRISPR off-target and DNA translocation" online in Nature Communications.

2022.07.07

Op-ed by Dr. Lijia Ma in Guangming Daily

On July 7, 2022, "Guangming Daily" published a signed article by Dr. Lijia Ma, the founder of Westlake Genetech, titled "Gene Editing: the "Magic Scissors of Life" for Correcting Errors".

2022.06.07

AI+Biotech | New Exploration of Combined Immunotherapy

On June 7, 2022, members of the founding team of Westlake Genetech published a paper titled "An in-library ligation strategy and its application in CRISPR/Cas9 screening of high-order gRNA combinations" online in Nucleic Acids Research.

2022.05.12

The Ground-breaking Ceremony of GMP R&D Laboratory

On May 12, 2022, the commencement ceremony for the renovation of the GMP R&D laboratory for gene and cell therapy of Westlake Genetech was held in Yunqi Town, marking the official launch of the Westlake Genetech Yunqi R&D platform project.